

Takeda

Grange Castle, Ireland

Foster Wheeler, in association with its Irish associate company PM, was awarded the EPC contract for an active pharmaceutical ingredients (API) facility at Grange Castle, Dublin, in December 2002 by Ishikawajima-Harima Heavy Industries Limited (IHI) of Japan.

This project, awarded by Takeda Pharma Ireland Ltd to IHI, represents the largest API manufacturing investment to date by Takeda outside Japan. The plant, which has been built on a 20-acre greenfield site, is designed for multipurpose use and initially will produce Takeda's blockbuster type 2 diabetes drug Actos.

The high standard of architectural design and landscaping reflects the exacting requirements of South Dublin County Council and the standard


already established by the adjacent Wyeth Biotech facility within Grange Castle Business Park, 10 km west of Dublin.

Design and construction was particularly complex: the facility needed to be highly automated to allow minimum operating personnel, and had to permit flexible production operation. To signify compliance with the essential safety requirements of EU Directives, Foster Wheeler has provided Takeda with a CE mark for the completed facility.

Construction, which began in January 2003, is now complete. IHI is continuing with qualification and validation activities prior to the final handover of the facility to Takeda.



Chris Whittle (middle), field engineering manager, FW, with CE plate; Les MacCormick (left), field superintendent, FW and Joe Hayes, field superintendent, PM.



Photos courtesy of Chapman Brown Photography